DDrare: Database of Drug Development for Rare Diseases

Searched query = "Prolactin secreting pituitary adenoma", "Pituitary PRL secretion hyperthyroidism", "Prolactinoma", "Prolactin secreting adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bromocriptine; Cabergoline; Clomiphene; Clomiphene citrate; Curcumin; Dexamethasone; Dopamine; Dopamine Agonists; Dopamine agonist treatment; Drug treatment; Gamma-secretase/Notch signalling pathway inhibitor RO4929097; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; HCQ/CQ and CAB combined treatment; Lapatinib; Other: Surgery; Other: diagnostic laboratory biomarker analysis; Other: pharmacological study; PASIREOTIDE; Pasireotide; Procedure: Endoscopic trans-sphenoidal adenoma resection; Procedure: transsphenoidal surgery treatment; Ropinirole; SOM230; SOMATROPIN; Somatropin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03400865 (ClinicalTrials.gov)	October 25, 2018	8/1/2018	Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas	The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas	Resistance, Disease;Prolactinoma	Drug: HCQ/CQ and CAB combined treatment	Zhebao Wu	Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital	Not yet recruiting	18 Years	70 Years	All	30	N/A	China

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03400865
(ClinicalTrials.gov)

October 25, 2018

8/1/2018

Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas

Resistance, Disease;Prolactinoma

Drug: HCQ/CQ and CAB combined treatment

Zhebao Wu

Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital

Not yet recruiting

18 Years

70 Years

All

N/A

China